Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder

Rebecca S. Nelken, Begüm Z. Özel, Ava R. Leegant, Juan C. Felix, Daniel R. Mishell

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Objective: The aim of this study was to compare the efficacy of the ultralow-dose estradiol vaginal ring with that of oral oxybutynin in the treatment of overactive bladder in postmenopausal women. Methods: Postmenopausal women with an overactive bladder were recruited from the general gynecology clinic. Participants were randomized to receive either the ultralow-dose estradiol vaginal ring or oral oxybutynin for 12 weeks. The primary outcome was a decrease in the number of voids in 24 hours. The secondary outcomes were quality-of-life questionnaires, vaginal pH levels, and vaginal maturation index. Results: Fifty-nine women were enrolled. Thirty-one were randomized to receive oxybutynin, whereas 28 received the estradiol vaginal ring. Women who received oxybutynin had a mean decrease of 3.0 voids per day, and women who received the vaginal ring had a mean decrease of 4.5 voids per day, with no significant difference between the groups. There was a significant improvement in Urogenital Distress Inventory and Incontinence Impact Questionnaire scores in both groups, with no significant difference in improvement between the two groups. Conclusions: Ultralow-dose estradiol-releasing vaginal ring and oral oxybutynin seem to be similarly effective in decreasing the number of daily voids in postmenopausal women with overactive bladder.

Original languageEnglish (US)
Pages (from-to)962-966
Number of pages5
JournalMenopause
Volume18
Issue number9
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Female Contraceptive Devices
Overactive Urinary Bladder
Estradiol
Therapeutics
Gynecology
oxybutynin
Quality of Life
Equipment and Supplies

Keywords

  • Estradiol vaginal ring
  • Overactive bladder
  • Oxybutynin
  • Vaginal estrogen

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. / Nelken, Rebecca S.; Özel, Begüm Z.; Leegant, Ava R.; Felix, Juan C.; Mishell, Daniel R.

In: Menopause, Vol. 18, No. 9, 09.2011, p. 962-966.

Research output: Contribution to journalArticle

Nelken, Rebecca S. ; Özel, Begüm Z. ; Leegant, Ava R. ; Felix, Juan C. ; Mishell, Daniel R. / Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. In: Menopause. 2011 ; Vol. 18, No. 9. pp. 962-966.
@article{2ed4cdf83a4e45eea5a1ada5a7e0486a,
title = "Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder",
abstract = "Objective: The aim of this study was to compare the efficacy of the ultralow-dose estradiol vaginal ring with that of oral oxybutynin in the treatment of overactive bladder in postmenopausal women. Methods: Postmenopausal women with an overactive bladder were recruited from the general gynecology clinic. Participants were randomized to receive either the ultralow-dose estradiol vaginal ring or oral oxybutynin for 12 weeks. The primary outcome was a decrease in the number of voids in 24 hours. The secondary outcomes were quality-of-life questionnaires, vaginal pH levels, and vaginal maturation index. Results: Fifty-nine women were enrolled. Thirty-one were randomized to receive oxybutynin, whereas 28 received the estradiol vaginal ring. Women who received oxybutynin had a mean decrease of 3.0 voids per day, and women who received the vaginal ring had a mean decrease of 4.5 voids per day, with no significant difference between the groups. There was a significant improvement in Urogenital Distress Inventory and Incontinence Impact Questionnaire scores in both groups, with no significant difference in improvement between the two groups. Conclusions: Ultralow-dose estradiol-releasing vaginal ring and oral oxybutynin seem to be similarly effective in decreasing the number of daily voids in postmenopausal women with overactive bladder.",
keywords = "Estradiol vaginal ring, Overactive bladder, Oxybutynin, Vaginal estrogen",
author = "Nelken, {Rebecca S.} and {\"O}zel, {Beg{\"u}m Z.} and Leegant, {Ava R.} and Felix, {Juan C.} and Mishell, {Daniel R.}",
year = "2011",
month = "9",
doi = "10.1097/gme.0b013e3182104977",
language = "English (US)",
volume = "18",
pages = "962--966",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder

AU - Nelken, Rebecca S.

AU - Özel, Begüm Z.

AU - Leegant, Ava R.

AU - Felix, Juan C.

AU - Mishell, Daniel R.

PY - 2011/9

Y1 - 2011/9

N2 - Objective: The aim of this study was to compare the efficacy of the ultralow-dose estradiol vaginal ring with that of oral oxybutynin in the treatment of overactive bladder in postmenopausal women. Methods: Postmenopausal women with an overactive bladder were recruited from the general gynecology clinic. Participants were randomized to receive either the ultralow-dose estradiol vaginal ring or oral oxybutynin for 12 weeks. The primary outcome was a decrease in the number of voids in 24 hours. The secondary outcomes were quality-of-life questionnaires, vaginal pH levels, and vaginal maturation index. Results: Fifty-nine women were enrolled. Thirty-one were randomized to receive oxybutynin, whereas 28 received the estradiol vaginal ring. Women who received oxybutynin had a mean decrease of 3.0 voids per day, and women who received the vaginal ring had a mean decrease of 4.5 voids per day, with no significant difference between the groups. There was a significant improvement in Urogenital Distress Inventory and Incontinence Impact Questionnaire scores in both groups, with no significant difference in improvement between the two groups. Conclusions: Ultralow-dose estradiol-releasing vaginal ring and oral oxybutynin seem to be similarly effective in decreasing the number of daily voids in postmenopausal women with overactive bladder.

AB - Objective: The aim of this study was to compare the efficacy of the ultralow-dose estradiol vaginal ring with that of oral oxybutynin in the treatment of overactive bladder in postmenopausal women. Methods: Postmenopausal women with an overactive bladder were recruited from the general gynecology clinic. Participants were randomized to receive either the ultralow-dose estradiol vaginal ring or oral oxybutynin for 12 weeks. The primary outcome was a decrease in the number of voids in 24 hours. The secondary outcomes were quality-of-life questionnaires, vaginal pH levels, and vaginal maturation index. Results: Fifty-nine women were enrolled. Thirty-one were randomized to receive oxybutynin, whereas 28 received the estradiol vaginal ring. Women who received oxybutynin had a mean decrease of 3.0 voids per day, and women who received the vaginal ring had a mean decrease of 4.5 voids per day, with no significant difference between the groups. There was a significant improvement in Urogenital Distress Inventory and Incontinence Impact Questionnaire scores in both groups, with no significant difference in improvement between the two groups. Conclusions: Ultralow-dose estradiol-releasing vaginal ring and oral oxybutynin seem to be similarly effective in decreasing the number of daily voids in postmenopausal women with overactive bladder.

KW - Estradiol vaginal ring

KW - Overactive bladder

KW - Oxybutynin

KW - Vaginal estrogen

UR - http://www.scopus.com/inward/record.url?scp=80052422184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052422184&partnerID=8YFLogxK

U2 - 10.1097/gme.0b013e3182104977

DO - 10.1097/gme.0b013e3182104977

M3 - Article

VL - 18

SP - 962

EP - 966

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 9

ER -